Bristol-myers

Email this page to a friend

Want news about Bristol-myers and more e-mailed to you? Click here for free email alerts

Comfortably Numb: How Psychiatry Is Medicating a Nation Charles Barber See book keywords and concepts

Which was nothing compared to the stock options held by the CEO of bristol-myers Squibb, which amounted to $227 million. And it's not just the CEOs: in 2000, the average unexercised stock options of the top executives at Merck were $73 million; at bristol-myers Squibb, $65 million; at Pfizer, $54 million; at Eli Lilly, $33 million.

Our Daily Meds: How the Pharmaceutical Companies Transformed Themselves into Slick Marketing Machines and Hooked the Nation on Prescription Drugs Melody Petersen See book keywords and concepts

The federal government then paid to manufacture the drug and to test it in patients, before granting a license to bristol-myers to sell it. In fact, of the nation's twenty-one most important drugs introduced between 1965 and 1992, fifteen were developed using knowledge from federal-funded research, according to a report in 2000 by the Joint Economic Committee of Congress, then headed by Republican senator Connie Mack. Among the drugs mentioned by that report was the cancer drug cisplatin.

You Don't Have to be Afraid of Cancer Anymore Bill Sardi See book keywords and concepts

Many executives involved in the $2 billion purchase of marketing rights for Erbitux by bristol-myers have resigned. [New York Times, Feb. 11, 2004] What, no treatment for metastasis? Again, Clifton Leaf of Fortune Magazine speaks out about the failings of cancer treatment. In the end, it is not localized tumors that kill people with cancer; it is the process of metastasis—an incredible 90% of the time. That's because when most malignant solid tumors are diagnosed, they are typically quite large already—the size of a grape, perhaps, with more than a billion cells in the tumor mass.

The Big Fat Health and Fitness Lie Craig Pepin-Donat See book keywords and concepts

This recall follows the removal of Serzone by bristol-myers from the Canadian and European markets on January 8, 2003, because it had been linked to 26 deaths. The drug was yanked off the Canadian and European market in January 2003, but it continued to sell here in the U.S. for another 14 months. The FDA issued a "black box warning" label regarding Serzone in 2001, because of a suspected side effect that could cause life-threatening damage to the liver. How about Redux or Fen-Phen?

PDR for Herbal Medicines, Fourth Edition Thomson Healthcare, Inc. See book keywords and concepts

Product Information: Reyataz (atazanavir). bristol-myers Squibb Company, Princeton, NJ (PI issued 6/2003) reviewed 7/2003. Product Information: Soriatane (acitretin). Roche Laboratores, Inc, Nutley, NJ; 4/2003. Product Information: Zomig (zolmitriptan tablets). Zeneca Pharmaceuticals, Wilmington, DE; 1999. Prost N. Tichadou L, Rodor F, et al: Interaction millcpcrtuis-venlafaxine (Article in French). Presse Med 29:1285-1286. 2000. Quandt J, Schmidt U, Schenk N. Ambulante Behandlung leichter und mittelschwerer depressiver Verstimmungen. Allgemeinarzt 2:97-102. 1993. Raffa RB.

Overtreated: Why Too Much Medicine Is Making Us Sicker and Poorer Shannon Brownlee See book keywords and concepts

Kathleen Slattery-Moschkau is a former rep who carried the bag for nine years for bristol-myers Squibb and Johnson & Johnson before quitting to write and direct Side Effects, an independent film about a fictional drug rep. She recalls that the pressure on reps to hit their quotas was intense. "If Pfizer was having a dinner at a really nice restaurant, you had to come up with [Green Bay] Packers tickets—and a bus to the game," she says. As reps upped the gift-giving ante, doctors began feeling entitled to increasingly luxurious favors.

Comfortably Numb: How Psychiatry Is Medicating a Nation Charles Barber See book keywords and concepts

And it's not just the CEOs: in 2000, the average unexercised stock options of the top executives at Merck were $73 million; at bristol-myers Squibb, $65 million; at Pfizer, $54 million; at Eli Lilly, $33 million.5 Even after the woes that Big Pharma experienced between 2004 and 2007—the withdrawal of Vioxx from the market, the loss of half of the injectable flu vaccines because of quality control problems, and a growing public awareness of profiteering and an all-too-cozy relationship with the Bush administration—no one should worry unduly about the industry's fortunes.

America Fooled: The Truth About Antidepressants, Antipsychotics and How We've Been Deceived Dr. Timothy Scott See book keywords and concepts

Wagner has received research support from Abbott, bristol-myers Squibb, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Organon, Pfizer, and Wyeth-Ayerst; has served as a National Institute of Mental Health consultant to Abbott, bristol-myers Squibb, Cyberonics, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Novartis, Otsuka, Janssen, Pfizer, and UCB Pharma; and has participated in speaker's bureaus for Abbott, Eli Lilly, GlaxoSmithKline, Forest Laboratories, Pfizer, and Novartis.2 The study's principal statistician was Dr. Ruoyong Yang. Both he and another of the study's authors, Dr.

Comfortably Numb: How Psychiatry Is Medicating a Nation Charles Barber See book keywords and concepts

There is a new magazine, bp (underwritten by Pfizer and bristol-myers Squibb), offering hope for people suffering from bipolar disorder. Monk, a show about a detective with obsessive-compulsive disorder who uses his illness adaptively to perceive things that normal people can't, is one of the most popular programs on cable television and has received a gaggle of Screen Actors Guild, Emmy, and Edgar awards.

America Fooled: The Truth About Antidepressants, Antipsychotics and How We've Been Deceived Dr. Timothy Scott See book keywords and concepts

Eleven of the 12 principal authors had financial ties with bristol-myers Squibb as did most of the study's 17 secondary authors. Two were employees of the company. Nearly all the authors received income from the drug manufacturer in one or more ways—as consultants, advisory board members, or as honorarium or grant recipients. The study itself was paid for by bristol-myers Squibb. That is not the end of the story.

Our Daily Meds: How the Pharmaceutical Companies Transformed Themselves into Slick Marketing Machines and Hooked the Nation on Prescription Drugs Melody Petersen See book keywords and concepts

Instead, bristol-myers was their licensed seller and marketer. The most troublesome problem with the Tufts estimate of the cost of discovering a drug, however, is that there is no way to verify it. The pharmaceutical companies' actual research costs are one of the world's most closely guarded industrial secrets. In the 1970s and 1980s the companies waged a decade-long legal battle to keep even government auditors from reviewing the costs of their research laboratories.

In 2001 Peter Dolan, a young executive who had made his early mark promoting Jell-O for General Foods, became the chief executive of bristol-myers Squibb. The drug company Novartis hired the Pepsi marketer Thomas Ebeling and by 2000 had given him responsibility for running its global pharmaceutical business. When Randall Tobias took over as the head of Eli Lilly in 1993, he had spent most of his career as an executive for the phone company AT&T.

Peter Ringrose, the scientist in charge of the company's laboratories, said that OSB meant that bristol-myers would put its research money behind the scientific projects that had the greatest potential to reap massive sales. That meant that experimental compounds that may have proved to be lifesaving for patients but could never bring in the sales of a megablockbuster would be licensed to other companies or set aside to gather dust on a laboratory shelf.

In 2002, for example, bristol-myers, Abbott Laboratories, and Eli Lilly halted or substantially reduced their efforts to discover antibiotics. These decisions affected all the world's populations, including Americans who had so overused the available antibiotics that doctors were finding more and more cases where the drugs no longer worked against lethal infections. Tens of thousands of Americans die every year from infections that were once easily remedied with an antibiotic.

These are the gifts and payments he has received from these companies in the last two years: January 17, dinner and drinks at Daniel, compliments of Forest Labs, value three hundred dollars; January 23, fee for speaking about a new asthma drug, compliments of GlaxoSmithKline, two thousand dollars; February 12 to 15, educational conference in Aspen, Colorado, sponsored by Pfizer, Merck, and bristol-myers Squibb, value of the corporate subsidies to Dr. Jones, twenty-five hundred dollars; and so on.

The Food-Mood Connection: Nutrition-based and Environmental Approaches to Mental Health and Physical Wellbeing Gary Null and Amy McDonald See book keywords and concepts

In one recent case, a Louisiana judge ordered bristol-myers Squibb, the company that manufactures and distributes Prolixin, to pay $2 million to a fifty-two-year-old woman who developed severe and disabling tardive dyskinesia after taking the drug for five years. Among her symptoms were muscle spasms and abnormal movements of the face, neck, shoulders, and extremities, as well as impaired speech and breathing. More than thirty years ago, according to Dr.

The Whistleblower: Confessions of a Healthcare Hitman Peter Rost See book keywords and concepts

The settlement concluded a two-year SEC investigation of the company, but the bad news for bristol-myers Squibb didn't stop there. A separate criminal investigation by the U.S. Attorney General's office in New Jersey resulted in the indictment of two executives: The former senior vice president and chief financial officer, and the former executive vice president and president of the bristol-myers Squibb's world-wide medicines group. Both were charged with securities fraud and conspiracy to commit securities fraud, for planning and executing channel stuffing at the company.

In 2004 the Securities and Exchange Commission (SEC) ordered bristol-myers Squibb to pay $ 150 million to settle charges that it inflated its revenue by $1.5 billion in 2000 and 2001. The penalty was one of the largest levied against a company accused of accounting fraud.26 The settlement concluded a two-year SEC investigation of the company, but the bad news for bristol-myers Squibb didn't stop there. A separate criminal investigation by the U.S.

Generation Rx: How Prescription Drugs are Altering American Lives, Minds, and Bodies Greg Critser See book keywords and concepts

At Abbott Laboratories, wrote its chairman, "We believe direct advertising to the consumer introduces a very real possibility of causing harm to patients who may respond to advertisements by pressuring physicians to prescribe medications that may not be required." At bristol-myers, said its chief executive, "We fail to understand a benefit to any audience" of DTC. Burroughs Wellcome worried that DTC could actually hurt the industry's ability to come up with new drugs because of "the potential for misdirection of industry efforts and resources.

Big Pharma: Exposing the Global Healthcare Agenda Jacky Law See book keywords and concepts

Pharma company, bristol-myers Squibb (BMS), was also thrown into some disarray because it had paid $2 billion for a 20% stake in ImClone plus the US marketing rights to Erbitux, the jewel in its crown. Even with all the due diligence a company the size of BMS can afford, still pharmaceuticals are a seriously risky business. All that changed, of course, when the concerns to do with the study design had been ironed out and Erbitux did get its first licence.

The drug, bristol-myers Squibb's cholestyramine, had to be sprinkled onto food making it taste ghastly, and two-thirds of those taking it reported side effects of constipation, gas, heartburn and bloating. After seven years of this ordeal, 30 of the 1,900 people taking the drug had suffered a fatal heart attack compared to 38 in the control group. This does correlate with a 25% drop in risk because the difference, eight, is roughly 25% of 38. But it took seven years and an awful lot of effort and expense to 'save' eight lives.

But others, such as bristol-myers Squibb, which markets one of the least potent statins, Pravachol, insist patients glean little incremental benefit by reducing their LDL levels too much. Doctors, and their patients, are naturally interested if lower really is better. But pharma companies are usually reluctant to pit their drugs against competitors in head-to-head studies, unless they have reason to believe the results would favour their product.

Lipitor. bristol-myers Squibb was naturally quick to point out that the images didn't actually prove anything; but to most people, Lipitor won convincingly. According to the Wall Street Journal, Pfizer said it intended to talk to the regulators about whether the findings are sufficient to change its product label so it can add the effect to its marketing programme.12 If validated in further studies, they could lead experts to lower national LDL for high-risk patients to below the current recommended level of 100. Then came the PROVE-IT study, the results of which were announced in March 2004.

This pitted an 80mg daily dose of Pfizer's Lipitor against a 40mg daily dose of bristol-myers Squibb's Pravachol in 4,000 patients who had been hospitalized for either acute heart attacks or unstable angina. This was funded by BMS in an attempt to show that lower was not necessarily better. The BMS drug was designed to reduce LDL cholesterol to 100, which according to US guidelines, is the target level for such patients. In contrast, the high-dose Lipitor was designed to reduce levels to 70, substantially lower than the guidelines.

Kirk Douglas, Pierce Brosnan and Angela Bassett are all reported to take bristol-myers Squibb's statin, Pravachol. Wyeth has used singer Patti LaBelle to promote Prempro hormone replacement therapy and engaged musical comedy stars Debbie Reynolds and Rita Moreno to urge women to have bone-density tests. Former Republican presidential candidate Bob Dole as well as Pele have both promoted Pfizer's Viagra. The practice grows because it works.

Generation Rx: How Prescription Drugs are Altering American Lives, Minds, and Bodies Greg Critser See book keywords and concepts

In 1981, Joe Davis was a senior advertising executive at the esteemed Ogilvy Agency in New York, overseeing a broad line of over-the-counter drug ads for bristol-myers and Ciba-Geigy. Davis had always been a bookish fellow, inclined toward tomes that, as he put it, "stretched my mind." One recently published polemic, Medical Nemesis, blew his mind. Nemesis was not exactly a New York Times bestseller, but its author, a former Catholic priest named Ivan Illich, managed to get his ideas out to a lot of influential people. He was a product of the times.

That limited him as a possible successor to Furlaud, who, unknown to Leschly, had quietly begun considering a merger of Squibb with the much larger bristol-myers. In late 1989, Furlaud announced that he was indeed merging with Bristol, and that, in keeping with the fact of Squibb's relatively smaller size, he would be assuming the presidency of its pharmaceutical operations — essentially taking Leschly's job. Seeing no possibility of emerging on top — his dream — Leschly resigned. For a year or so, he was rarely seen in the leafy New Jersey suburb where he lived.

The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet, Weight Loss and Long-term Health T. Colin Campbell, Ph.D. and Thomas M. Campbell II See book keywords and concepts

The Dannon Institute, Egg Nutrition Board, National Cattlemen's Beef Association, National Dairy Council, Nestle Clinical Nutrition, Wyeth-Ayerst Laboratories, bristol-myers Squibb Company, Baxter Healthcare Corporation and others have all joined forces to produce a Nutrition in Medicine program and the Medical Nutrition Curriculum Initiative.9'10 Do you think that this all-star team of animal foods and drug industries representatives is going to objectively judge and promote optimal nutrition, which science has shown to be a whole foods, plant-based diet that minimizes the need for drugs?

Generation Rx: How Prescription Drugs are Altering American Lives, Minds, and Bodies Greg Critser See book keywords and concepts

In 2000 the CEO of bristol-myers Squibb sent urgent messages to all of his company's top managers to "donate the maximum" to the Bush campaign, $1,000 individually and $1,000 in their spouse's name; the company itself ponied up $2 million. In 2002, seeing that some form of prescription drug bill was inevitable, Holmer and his companies targeted $26 million for local congressional races. They also ratcheted up old-fashioned, buttonhole lobbying. By 2002 there were six pharma lobbyists for every sitting U.S. senator, a kind of political day care for potentially errant legislators.

page 1 of 4 | Next ->

FAIR USE NOTICE: The research quoted here is provided under the protection of Fair Use provisions and published by the 501(c)3 non-profit Consumer Wellness Center for the purposes of public comment and education. Authors / publishers may submit books for consideration of inclusion here.

TERMS OF USE: Read full terms of use. Citations of text from NaturalPedia must include: 1) Full credit to the original author and book title. 2) Secondary credit to the Natural News Naturalpedia as a research resource and a link to www.NaturalNews.com/np/index.html

This unique compilation of research is copyright (c) 2008 by the non-profit Consumer Wellness Center.

ABOUT THE CREATOR OF NATURALPEDIA: Mike Adams, the creator of this NaturalNews Naturalpedia, is the editor of NaturalNews.com, the internet's top natural health news site, creator of the Honest Food Guide (www.HonestFoodGuide.org), a free downloadable consumer food guide based on natural health principles, author of Grocery Warning, The 7 Laws of Nutrition, Natural Health Solutions, and many other books available at www.TruthPublishing.com, creator of the earth-friendly EcoLEDs company (www.EcoLEDs.com) that manufactures energy-efficient LED lighting products, founder of Arial Software (www.ArialSoftware.com), a permission e-mail technology company, creator of the CounterThink Cartoon series (www.NaturalNews.com/index-cartoons.html) and author of over 1,500 articles, interviews, special reports and reference guides available at www.NaturalNews.com. Adams' personal philosophy and health statistics are available at www.HealthRanger.org.